Depressive disorders are the most frequent psychiatric comorbidity in people with epilepsy, with lifetime prevalence rates of 30–35 %. Their prevalence is also higher than in the general population, and in particular, in people with poorly controlled seizures. In addition, there is a complex relation between epilepsy and depressive disorders, whereby not only are patients with epilepsy at greater risk of developing depressive disorders, but patients with primary depressive disorders are at greater risk of developing epilepsy. In this chapter, we review the salient aspects of depressive disorders in epilepsy that any clinician treating people with epilepsy must know.


Major Depressive Disorder Postictal Depression Ictal Depression Suicidality Antidepressant Drugs 


  1. 1.
    Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48(12):2336–44.PubMedGoogle Scholar
  2. 2.
    Edeh J, Toone B. Relationship between interictal psychopathology and the type of epilepsy. Results of a survey in general practice. Br J Psychiatry. 1987;151:95–101.CrossRefPubMedGoogle Scholar
  3. 3.
    Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia. 1996;37(2):148–61.CrossRefPubMedGoogle Scholar
  4. 4.
    O'Donoghue MF, Goodridge DM, Redhead K, Sander JW, Duncan JS. Assessing the psychosocial consequences of epilepsy: a community-based study. Br J Gen Pract. 1999;49(440):211–4.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Ettinger A, Reed M, Cramer J. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology. 2004;63(6):1008–14.CrossRefPubMedGoogle Scholar
  6. 6.
    Caplan R, Siddarth P, Gurbani S, Hanson R, Sankar R, Shields WD. Depression and anxiety disorders in pediatric epilepsy. Epilepsia. 2005;46(5):720–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav. 2000;1(2):100–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Ettinger AB, Weisbrot DM, Nolan EE, Gadow KD, Vitale SA, Andriola MR, et al. Symptoms of depression and anxiety in pediatric epilepsy patients. Epilepsia. 1998;39(6):595–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol. 2006;5(5):399–405.CrossRefPubMedGoogle Scholar
  11. 11.
    Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72:184–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Adelow C, Anderson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology. 2012;78:396–401.CrossRefPubMedGoogle Scholar
  13. 13.
    Forsgren L, Nystrom L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res. 1990;6(1):66–81.CrossRefPubMedGoogle Scholar
  14. 14.
    Dc H, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol. 2000;47(2):246–9.CrossRefGoogle Scholar
  15. 15.
    Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol. 2006;59(1):35–41.CrossRefPubMedGoogle Scholar
  16. 16.
    Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;62(4):345–54.CrossRefPubMedGoogle Scholar
  17. 17.
    Kanner AM. Depression and epilepsy: how can we explain their bidirectional relation? Epilepsia. 2011;52 Suppl 1:21–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Specchio LM, Iudice A, Specchio N, La Neve A, Spinelli A, Galli R, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol. 2004;27(3):133–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. The anticonvulsant effect of fluoxetine in humans. Neurology. 1995;45:1926.CrossRefPubMedGoogle Scholar
  20. 20.
    Favale E, Audenino D, Cocito L, Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure. 2003;12(5):316–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol. 2012;11(12):1093–102.CrossRefPubMedGoogle Scholar
  22. 22.
    Jobe PC. Affective disorder and epilepsy comorbidity in the genetically epilepsy prone-rat (GEPR). In: Gilliam FG, Kanner AM, Sheline YI, editors. Depression and brain dysfunction. London: Taylor & Francis; 2006. p. 121–57.Google Scholar
  23. 23.
    Mazarati AM, Siddarth P, Baldwin RA, et al. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain. 2008;131:2071–83.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Kumar G, Couper A, O'Brien TJ, Salzberg MR, Jones NC, Rees SM, Morris MJ. The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology. 2007;32(7):834–42.CrossRefPubMedGoogle Scholar
  25. 25.
    Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Zarate Jr CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64.CrossRefPubMedGoogle Scholar
  27. 27.
    Rajkowska G, O’Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology. 2007;32:471–82.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Vezzani A, Conti M, De Luigi A, Ravizza T, Moneta D, Marchesi F, De Simoni MG. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci. 1999;19:5054–65.PubMedGoogle Scholar
  29. 29.
    Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, et al. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci U S A. 2000;97:11534–9.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Vezzani A, Balosso S, Ravizza T. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun. 2008;22:797–803.CrossRefPubMedGoogle Scholar
  31. 31.
    Mendez MF, Cummings JL, Benson DF. Depression in epilepsy. Significance and phenomenology. Arch Neurol. 1986;43(8):766–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Kraepelin E. Psychiatrie, vol. 3. Leipzig: Barth; 1923.Google Scholar
  33. 33.
    Blumer D, Zielinksi J. Pharmacologic treatment of psychiatric disorders associated with epilepsy. J Epilepsy. 1988;1:135–50.CrossRefGoogle Scholar
  34. 34.
    Mula M, Jauch R, Cavanna A, Collimedaglia L, Barbagli D, Gaus V, et al. Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. Epilepsia. 2008;49(4):650–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Kanner AM, Barry JJ, Gilliam F, Hermann B, Meador KJ. Anxiety disorders, subsyndromic depressive episodes, and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy? Epilepsia. 2010;51(7):1152–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Blanchet P, Frommer GP. Mood change preceding epileptic seizures. J Nerv Ment Dis. 1986;174(8):471–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Williams D. The structure of emotions reflected in epileptic experiences. Brain. 1956;79(1):29–67.CrossRefPubMedGoogle Scholar
  38. 38.
    Daly D. Ictal affect. Am J Psychiatry. 1958;115(2):97–108.CrossRefPubMedGoogle Scholar
  39. 39.
    Weil A. Depressive reactions associated with temporal lobe uncinate seizures. J Nerv Ment Dis. 1955;121:505–10.CrossRefPubMedGoogle Scholar
  40. 40.
    Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology. 2004;62(5):708–13.CrossRefPubMedGoogle Scholar
  41. 41.
    Landoldt H. Some clinical electroencephalographical correlations in epileptic psychosis (twilight states). Electroencephalogr Clin Neurophysiol. 1953;5:121 (abstract).Google Scholar
  42. 42.
    Savard G, Andermann LF, Reutens D, Andermann F. Epilepsy, surgical treatment and postoperative psychiatric complications: A re-evaluation of the evidence. In: Trimble M, Schmitz B, editors. Forced normalization and alternative psychosis of epilepsy. Petersfield: Writson Biomedical Publishing Ltd.; 1998. p. 179–92.Google Scholar
  43. 43.
    McConnell H, Duncan D. Chapter 10: Treatment of psychiatric comorbidity in epilepsy. In: McConnell H, Snyder P, editors. Psychiatric comorbidity in epilepsy. Washington: American Psychiatric Press; 1998. p. 245–361.Google Scholar
  44. 44.
    Barabas G, Matthews WS. Barbiturate anticonvulsants as a cause of severe depression. Pediatrics. 1988;82(2):284–5.PubMedGoogle Scholar
  45. 45.
    Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics. 1987;80(6):909–17.PubMedGoogle Scholar
  46. 46.
    Ferrari M, Barabas G, Matthews WS. Psychologic and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. Am J Psychiatry. 1983;140(1):112–3.CrossRefPubMedGoogle Scholar
  47. 47.
    Ring HA, Reynolds EH. Vigabatrin and behaviour disturbance. Lancet. 1990;335(8695):970.CrossRefPubMedGoogle Scholar
  48. 48.
    McConnell H, Snyder PJ, Duffy JD, Weilburg J, Valeriano J, Brillman J, et al. Neuropsychiatric side effects to treatment with Felbamate. J Neuropsych Clin Neurosci. 1996;8(3):341–6.CrossRefGoogle Scholar
  49. 49.
    Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61:704–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Trimble RM, Rϋsch N, Betts T, Crawford PM. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure. 2000;9:249–54.CrossRefPubMedGoogle Scholar
  51. 51.
    Ketter TA, Malow BA, Flamini R, White SR, Post RM, Theodore WH. Anticonvulsant withdrawal-emergent psychopathology. Neurology. 1994;44(1):55–61.CrossRefPubMedGoogle Scholar
  52. 52.
    Barclay L. FDA requires warnings about suicidality risk with antiepileptic drugs. Medscape Medical News. 2008.
  53. 53.
    Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: fire or false alarm? Epilepsia. 2009;50(5):978–86.CrossRefPubMedGoogle Scholar
  54. 54.
    Kanner AM, Balabanov AJ. Chapter 133a: Psychiatric outcome of epilepsy surgery. In: Lüders HO, Bongaman W, Najim IM, editors. Textbook of epilepsy surgery. 3rd ed. London: Informa Healthcare; 2008. p. 1254–62.CrossRefGoogle Scholar
  55. 55.
    Koch-Stoecker S. Psychiatric effects of surgery for temporal lobe epilepsy. In: Trimble M, Schmitz B, editors. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press; 2002. p. 266–82.CrossRefGoogle Scholar
  56. 56.
    Fazel S, Wolf A, Långström N, Newton CR, Lichtenstein P. Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study. Lancet. 2013;382(9905):1646–54.PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007;6(8):693–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Jones JE, Hermann BP, Barry JJ, Gilliam FG, Kanner AM, Meador KJ. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav. 2003;4(3):31–8.CrossRefGoogle Scholar
  59. 59.
    Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EK, Thurman DJ, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology. 2011;76(3):273–9.PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Kanner AM, Barry JJ, Gilliam F, Hermann B, Meador KJ. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia. 2012;53(6):1104–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Petrovski S, Szoeke CE, Jones NC, Salzberg MR, Sheffield LJ, Huggins RM, O’Brien TJ. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology. 2010;75(11):1015–21.CrossRefPubMedGoogle Scholar
  62. 62.
    Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Res. 2007;75(2–3):192–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Kanner AM, Byrne R, Chicharro A, Wuu J, Frey M. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology. 2009;72(9):793–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Cleary RA, Thompson PJ, Fox Z, Foong J. Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery. Epilepsia. 2012;53(10):1705–12.CrossRefPubMedGoogle Scholar
  65. 65.
    de Araújo Filho GM, Gomes FL, Mazetto L, Marinho MM, Tavares IM, Caboclo LO, et al. Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis. Seizure. 2012;8:619–23.CrossRefGoogle Scholar
  66. 66.
    Cramer JA, Blum M, Reed M, Fanning K, Project EI. The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav. 2003;4:515–21.CrossRefPubMedGoogle Scholar
  67. 67.
    Lehrner J, Kalchmayr R, Serles W, Olbrich A, Pataraia E, Aull S, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure. 1999;8(2):88–92.CrossRefPubMedGoogle Scholar
  68. 68.
    Gilliam F, Kuzniecky R, Faught E, Black L, Carpenter G, Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia. 1997;38(2):233–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Perrine K, Hermann BP, Meador KJ, Vickrey BG, Cramer JA, Hays RD, Devinsky O. The relationship of neuropsychological functioning to quality of life in epilepsy [see comments]. Arch Neurol. 1995;52(10):997–1003.CrossRefPubMedGoogle Scholar
  70. 70.
    Cramer JA, Blum D, Fanning K, Reed M, Epilepsy Impact Project Group. The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav. 2004;5:337–42.CrossRefPubMedGoogle Scholar
  71. 71.
    Jones JE, Watson R, Sheth R, Caplan R, Koehn M, Seidenberg M, Hermann B. Psychiatric comorbidity in children with new onset epilepsy. Dev Med Child Neurol. 2007;49(7):493–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146:317–25.CrossRefPubMedGoogle Scholar
  73. 73.
    Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav. 2008;13(Suppl1):S1–29.CrossRefPubMedGoogle Scholar
  74. 74.
    Kerr MP, Mensah S, Besag F, de Toffol B, Ettinger A, Kanemoto K, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52(11):2133–8.CrossRefPubMedGoogle Scholar
  75. 75.
    Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand. 1991;84(6):583–4.CrossRefPubMedGoogle Scholar
  76. 76.
    Grimsley SR, Jann MW, Carter JG, D’Mello AP, D'SouzaM J. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991;50(1):10–5.CrossRefPubMedGoogle Scholar
  77. 77.
    Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry. 1990;51(3):126.PubMedGoogle Scholar
  78. 78.
    Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol. 1997;17(2):107–9.CrossRefPubMedGoogle Scholar
  79. 79.
    Fink M, Kellner CH, Sackeim HA. Intractable seizures, status epilepticus, and ECT. J ECT. 1999;15(4):282–4.CrossRefPubMedGoogle Scholar
  80. 80.
    Regenold WT, Weintraub D, Taller A. Electroconvulsive therapy for epilepsy and major depression. Am J Geriatr Psychiatry. 1998;6(2):180–3.CrossRefPubMedGoogle Scholar
  81. 81.
    Blackwood DH, Cull RE, Freeman CP, Evans JI, Mawdsley C. A study of the incidence of epilepsy following ECT. J Neurol Neurosurg Psychiatry. 1980;43(12):1098–102.PubMedCentralCrossRefPubMedGoogle Scholar
  82. 82.
    Marangell LB, Rush AJ, George MS, Sackeim HA, Johnson CR, Husain MM, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51(4):280–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Epilepsy Section, Department of NeurologyComprehensive Epilepsy Center, University of Miami, Miller School of MedicineMiamiUSA
  2. 2.EEG Monitoring UnitUniversity of Miami Hospital, University of Miami, Miller School of MedicineMiamiUSA

Personalised recommendations